TY - JOUR
T1 - Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma
AU - Frustaci, Sergio
AU - Gasparini, Giampietro
AU - Veronesi, Andrea
AU - Tirelli, Umberto
AU - Pacciarini, Maria Adele
AU - Crivellari, Diana
AU - Zagonel, Vittorina
AU - Monfardini, Silvio
PY - 1987/9
Y1 - 1987/9
N2 - Sixteen patients with locally advanced or metastatic head and neck cancer were treated with esorubicin (4t'-deoxydoxorubicin) at a dose of 30-35 mg/m2 i.v. every 3 weeks. One patient was lost to the follow up after one cycle, whereas in the 15 evaluable cases a total of 34 courses were administered (median per patient: 2, range: 1-6). Pretreatment for parameter lesions consisted of radiotherapy in 5, chemotherapy in 3 and both treatments in 1 patients respectively. Overall, one partial response, one stable disease and 13 progressions were documented. Severe (grade 3 and 4) leukopenia, thrombocytopenia and anemia were noted in 3, 1 and 1 patients respectively. The only patient developing leukopenia and thrombocytopenia of grade 4 subsequently died because of pneumonia. On the other hand, non-hematologic toxicity was generally mild. At this dose and schedule, esorubicin demonstrated an activity less than 20% in head and neck cancer and therefore, no further evaluation is warranted.
AB - Sixteen patients with locally advanced or metastatic head and neck cancer were treated with esorubicin (4t'-deoxydoxorubicin) at a dose of 30-35 mg/m2 i.v. every 3 weeks. One patient was lost to the follow up after one cycle, whereas in the 15 evaluable cases a total of 34 courses were administered (median per patient: 2, range: 1-6). Pretreatment for parameter lesions consisted of radiotherapy in 5, chemotherapy in 3 and both treatments in 1 patients respectively. Overall, one partial response, one stable disease and 13 progressions were documented. Severe (grade 3 and 4) leukopenia, thrombocytopenia and anemia were noted in 3, 1 and 1 patients respectively. The only patient developing leukopenia and thrombocytopenia of grade 4 subsequently died because of pneumonia. On the other hand, non-hematologic toxicity was generally mild. At this dose and schedule, esorubicin demonstrated an activity less than 20% in head and neck cancer and therefore, no further evaluation is warranted.
KW - esorubicin
KW - head and neck cancer
UR - http://www.scopus.com/inward/record.url?scp=0023192288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023192288&partnerID=8YFLogxK
U2 - 10.1007/BF00175303
DO - 10.1007/BF00175303
M3 - Article
C2 - 3667167
AN - SCOPUS:0023192288
VL - 5
SP - 307
EP - 309
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 3
ER -